Elite *Journal of Scientific Research and Review*. Volume 2 issue 2(2024), Pp. 1-16
https://epjournals.com/journals/EJSRR

Platelet Dysfunction in HIV Patients: Assessing ART Risks

[*]Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Platelet dysfunction is increasingly recognized as a significant complication in individuals living with human immunodeficiency virus (HIV), with implications for disease progression, coagulopathy, and cardiovascular risk. While antiretroviral therapy (ART) has transformed the management of HIV by suppressing viral replication and restoring immune function, emerging evidence suggests potential risks associated with ART-induced platelet dysfunction. This review examines the multifaceted relationship between platelet dysfunction and HIV infection, with a focus on the potential risks associated with ART. We explore the pathophysiology of platelet dysfunction in HIV, the impact of ART on platelet function, and the clinical implications for HIV-infected individuals. Additionally, we discuss strategies for assessing and managing platelet dysfunction in the context of ART. Understanding the interplay between HIV infection, ART, and platelet dysfunction is crucial for optimizing patient care and minimizing treatment-related complications in HIV-infected individuals.

Keywords: *Platelet dysfunction, HIV, antiretroviral therapy, ART, coagulopathy, cardiovascular risk, thrombosis, immune activation*

Introduction

Platelet dysfunction is increasingly recognized as a significant complication in individuals living with human immunodeficiency virus (HIV), exerting profound implications for disease progression, coagulopathy, and cardiovascular risk. While antiretroviral therapy (ART) has transformed the management of HIV by effectively suppressing viral replication and restoring immune function, emerging evidence suggests potential risks associated with ART-induced

platelet dysfunction. The complex interplay between HIV infection, immune activation, and platelet function underscores the need for a comprehensive understanding of the pathophysiology underlying platelet dysfunction in the context of HIV. HIV infection is characterized by chronic immune activation and inflammation, which contribute to endothelial dysfunction and alterations in platelet function. Viral replication and immune dysregulation directly impact megakaryocyte function and platelet production, leading to qualitative and quantitative changes in platelet function. Furthermore, HIV-associated coagulopathy and thrombocytopenia are common hematologic manifestations, further exacerbating platelet dysfunction and increasing the risk of bleeding and thrombotic events in HIV-infected individuals.[1-24]

While ART has revolutionized the management of HIV by effectively suppressing viral replication and restoring immune function, certain antiretroviral agents have been implicated in exacerbating platelet dysfunction. Protease inhibitors, nucleoside reverse transcriptase inhibitors, and other components of ART regimens have been associated with adverse effects on platelet function, such as impaired aggregation and altered expression of surface receptors. Understanding the potential risks associated with ART-induced platelet dysfunction is essential for optimizing treatment strategies and improving outcomes in HIV-infected individuals. The clinical implications of platelet dysfunction in HIV are far-reaching, encompassing increased risks of bleeding, thrombosis, and cardiovascular events. Coagulopathy and thrombocytopenia are prevalent hematologic abnormalities in HIV-infected individuals, with implications for treatment management and clinical outcomes. Furthermore, platelet dysfunction may contribute to immune activation, inflammation, and endothelial dysfunction, thereby exacerbating HIV-associated complications and influencing disease progression. Given the multifactorial nature of platelet dysfunction in HIV and the potential risks associated with ART, there is a critical need for tailored approaches to assessing and managing platelet function in HIV-infected individuals. Clinicians should consider individual patient factors, including underlying comorbidities, concomitant medications, and ART regimen, when evaluating the risk of platelet dysfunction and implementing appropriate management strategies. By understanding the complex interplay between HIV infection, ART, and platelet dysfunction, clinicians can optimize treatment outcomes and reduce complications in individuals living with HIV.[25-49]

Platelet Dysfunction in HIV: Pathophysiology and Mechanisms

Platelet dysfunction in HIV infection represents a multifaceted phenomenon influenced by various pathophysiological mechanisms, including direct viral effects, immune activation, endothelial dysfunction, and medication-related factors. Chronic immune activation and inflammation are hallmark features of HIV infection, contributing significantly to platelet dysfunction. HIV-induced immune activation leads to systemic inflammation, resulting in endothelial activation and dysfunction. Activated endothelial cells release pro-inflammatory cytokines and express adhesion molecules, such as P-Selectin, promoting platelet adhesion and aggregation. Moreover, immune activation stimulates platelet production and turnover, leading to qualitative and quantitative changes in platelet function. Direct viral effects on platelets and megakaryocytes also contribute to platelet dysfunction in HIV. HIV can directly infect megakaryocytes, the precursor cells of platelets, disrupting their maturation and function. Viral proteins, such as gp120 and Tat, interact

with platelet receptors and signaling pathways, impairing platelet activation and aggregation. Additionally, HIV-induced immune dysregulation alters the bone marrow microenvironment, further impacting megakaryopoiesis and platelet production.[50-74]

Endothelial dysfunction, a common feature of HIV infection, plays a pivotal role in mediating platelet dysfunction. HIV-induced endothelial activation and dysfunction result in increased expression of adhesion molecules, pro-thrombotic factors, and von Willebrand factor (vWF). These changes promote platelet adhesion, activation, and aggregation, contributing to thrombotic risk and cardiovascular complications in HIV-infected individuals. Medication-related factors, particularly antiretroviral therapy (ART), may exacerbate platelet dysfunction in HIV. Certain classes of ART, such as protease inhibitors and nucleoside reverse transcriptase inhibitors, have been associated with adverse effects on platelet function, including impaired aggregation and altered expression of surface receptors. These effects may contribute to the development of coagulopathy, thrombotic events, and cardiovascular complications in HIV-infected individuals receiving ART.[75-98]

Impact of ART on Platelet Function

Antiretroviral therapy (ART) has revolutionized the management of human immunodeficiency virus (HIV) infection by effectively suppressing viral replication and restoring immune function. However, emerging evidence suggests that certain components of ART regimens may exert adverse effects on platelet function, thereby impacting hemostasis, thrombosis, and cardiovascular risk in HIV-infected individuals. Protease inhibitors (PIs), a class of antiretroviral agents commonly used in ART regimens, have been implicated in impairing platelet function through various mechanisms. PIs, such as ritonavir and lopinavir, have been shown to inhibit platelet aggregation and secretion by interfering with intracellular signaling pathways involved in platelet activation. Additionally, PIs may induce endothelial dysfunction and alter the balance of pro- and anti-thrombotic factors, further exacerbating platelet dysfunction and increasing the risk of thrombotic events in HIV-infected individuals receiving PI-based ART regimens. Nucleoside reverse transcriptase inhibitors (NRTIs), another class of antiretroviral agents commonly used in ART regimens, have also been associated with adverse effects on platelet function. Certain NRTIs, such as zidovudine and stavudine, have been shown to induce mitochondrial toxicity and oxidative stress in platelets, leading to impaired aggregation and increased platelet turnover. Moreover, NRTIs may alter platelet membrane composition and receptor expression, further contributing to platelet dysfunction and thrombotic risk in HIV-infected individuals. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, and other components of ART regimens may also exert effects on platelet function, although the mechanisms underlying these effects are less well understood. NNRTIs, such as efavirenz and nevirapine, have been reported to induce hepatic enzyme induction and alter platelet metabolism, potentially affecting platelet aggregation and activation. Integrase inhibitors, such as raltegravir and dolutegravir, have been associated with changes in lipid metabolism and endothelial function, which may indirectly impact platelet function in HIV-infected individuals.[99-120]

Clinical Implications of Platelet Dysfunction in HIV Patients

Platelet dysfunction represents a significant clinical concern in individuals living with human immunodeficiency virus (HIV), exerting profound implications for disease progression, coagulopathy, and cardiovascular risk. One of the primary clinical implications of platelet dysfunction in HIV patients is an increased risk of bleeding complications. Platelet dysfunction, characterized by impaired aggregation and secretion, predisposes HIV-infected individuals to mucocutaneous bleeding, petechiae, and ecchymoses. Thrombocytopenia, a common hematologic manifestation of HIV, further exacerbates bleeding risk in these patients. Clinicians should be vigilant for signs of bleeding and monitor platelet counts and function in HIV-infected individuals, particularly those with advanced disease or concomitant anticoagulant therapy. Thrombotic events, including venous thromboembolism and arterial thrombosis, are also prevalent complications of platelet dysfunction in HIV patients. HIV-induced immune activation and inflammation promote a prothrombotic state, contributing to endothelial dysfunction and platelet activation. Additionally, certain components of antiretroviral therapy (ART), such as protease inhibitors and nucleoside reverse transcriptase inhibitors, may further exacerbate thrombotic risk by impairing platelet function and altering coagulation pathways. Clinicians should be aware of the increased thrombotic risk in HIV-infected individuals and consider thromboprophylaxis strategies in high-risk patients, particularly those with additional cardiovascular risk factors or a history of thrombotic events.[121-123]

Cardiovascular complications, including myocardial infarction, stroke, and peripheral arterial disease, are significant clinical consequences of platelet dysfunction in HIV patients. Platelet dysfunction and thrombotic events contribute to accelerated atherosclerosis and endothelial dysfunction, leading to increased cardiovascular morbidity and mortality in HIV-infected individuals. Moreover, HIV-associated coagulopathy and inflammation further exacerbate cardiovascular risk in these patients. Clinicians should carefully assess cardiovascular risk factors and implement aggressive management strategies, including lifestyle modifications, lipid-lowering therapy, and antiplatelet agents, to reduce cardiovascular risk in HIV-infected individuals. Neurological complications, such as HIV-associated neurocognitive disorders (HAND), are prevalent in HIV-infected individuals and are associated with platelet dysfunction and thrombotic events. Platelet dysfunction and thrombosis contribute to neuroinflammation, neuronal injury, and cognitive impairment in HIV patients. Clinicians should be vigilant for signs of cognitive decline and implement neuroprotective strategies, including antiretroviral therapy and antiplatelet agents, to preserve cognitive function in HIV-infected individuals.1[24-16]

Assessing ART Risks and Managing Platelet Dysfunction

Antiretroviral therapy (ART) has transformed the management of human immunodeficiency virus (HIV) infection, significantly improved patient outcomes and reducing mortality. However, the potential risks associated with ART-induced platelet dysfunction must be carefully considered in HIV-infected individuals to optimize treatment strategies and minimize treatment-related complications. Assessing the risks associated with ART-induced platelet dysfunction requires a comprehensive approach, taking into account various factors, including the specific ART regimen, patient characteristics, and underlying comorbidities. Clinicians should be aware of the potential adverse effects of different classes of antiretroviral agents on platelet function and carefully

evaluate individual patient risk profiles when selecting ART regimens. Monitoring platelet function and thrombotic risk is essential for assessing ART-related risks and managing platelet dysfunction in HIV-infected individuals. Regular monitoring of platelet counts, aggregation assays, and coagulation parameters can help identify individuals at increased risk of bleeding or thrombosis and guide treatment decisions accordingly. Additionally, assessing cardiovascular risk factors, such as hypertension, dyslipidemia, and smoking, is crucial for optimizing cardiovascular health in HIV-infected individuals receiving ART.[127]

Modifying ART regimens may be necessary in HIV-infected individuals with significant platelet dysfunction or thrombotic risk. Switching to alternative antiretroviral agents with a lower propensity to impair platelet function, such as integrase inhibitors or non-nucleoside reverse transcriptase inhibitors, may be considered in individuals experiencing adverse effects on platelet function with their current ART regimen. Additionally, adjunctive therapies, such as antiplatelet agents or anticoagulants, may be indicated in HIV-infected individuals at increased risk of thrombotic events. Lifestyle modifications, including smoking cessation, regular exercise, and adherence to a healthy diet, can also help mitigate platelet dysfunction and reduce cardiovascular risk in HIV-infected individuals. Smoking cessation, in particular, has been shown to improve platelet function and reduce cardiovascular risk in HIV-infected individuals receiving ART. Moreover, promoting a healthy lifestyle and addressing modifiable risk factors can complement pharmacological interventions in optimizing cardiovascular health in this population.[127]

Conclusion

Platelet dysfunction represents a significant clinical concern in individuals living with human immunodeficiency virus (HIV), with implications for disease progression, coagulopathy, and cardiovascular risk. While antiretroviral therapy (ART) has revolutionized the management of HIV by effectively suppressing viral replication and restoring immune function, certain components of ART regimens may exacerbate platelet dysfunction through various mechanisms. Understanding the complex interplay between HIV infection, ART, and platelet dysfunction is crucial for optimizing treatment strategies and improving clinical outcomes in HIV-infected individuals. The clinical implications of platelet dysfunction in HIV patients are far-reaching, encompassing increased risks of bleeding, thrombosis, cardiovascular events, and neurological disorders. Clinicians must be vigilant for signs of bleeding or thrombosis and carefully assess cardiovascular risk factors in HIV-infected individuals receiving ART. Regular monitoring of platelet function and thrombotic risk is essential for identifying individuals at increased risk of complications and guiding treatment decisions accordingly.

Assessing ART-related risks and managing platelet dysfunction in HIV-infected individuals require a comprehensive approach, involving careful evaluation of individual patient risk profiles, regular monitoring of platelet function and thrombotic risk, modification of ART regimens when necessary, and implementation of adjunctive therapies and lifestyle modifications to optimize cardiovascular health. By adopting a personalized approach to managing platelet dysfunction in HIV-infected individuals, clinicians can minimize treatment-related complications and improve long-term outcomes in this population.

Citation: Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 1-16

References

1. Vishnu P, Aboulafia DM. Haematological manifestations of human immune deficiency virus infection. British journal of haematology. 2015;171(5):695-709.
2. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thrombosis research. 2012;129(3):301-318.
3. Gresele P, Falcinelli E, Momi S, Francisci D, Baldelli F. Highly active antiretroviral therapy–related mechanisms of endothelial and platelet function alterations. Reviews in cardiovascular medicine. 2014;15(S1):9-20.
4. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
5. Obeagu EI, Obeagu GU. Studies on platlets diagnostic indexes in patients with acute myeloid leukaemia in Uganda. Int. J. Curr. Res. Med. Sci. 2023;9(1):24-27.
6. Obeagu EI, Okechukwu PU, Alum EU, Obeagu GU, Opoku D, Scott GY, Amekpor F. Platelets as actors in inflammation and immunity: A fulcrum in immunity. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
7. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets and Some Inflammation Markers of Patients with Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(3):78-84.
8. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
9. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
10. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
11. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
12. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
13. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
14. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa

State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
15. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
16. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
17. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
18. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
19. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
20. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
21. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
22. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
23. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
24. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
25. Ifeanyi OE, Favour AA, Prayer NN. Updates on Human Immunodeficiency Virus and Platelets. Int. J. Adv. Res. Biol. Sci. 2020;7(6):1-7.

26. Obeagu EI, Muhimbura E, Kagenderezo BP, Nakyeyune S, Obeagu GU. An Insight of Interleukin-6 and Fibrinogen: In Regulating the Immune System. J Biomed Sci. 2022;11(10):83.
27. Okoroiwu IL, Obeagu EI, Vivian Egwim V. Assessment of White Blood Cell Count and Platelet Count in Women on Hormonal Contraceptives in Owerri, Imo State, Nigeria. J Res Med Dent Sci. 2021;9(12):498-501.
28. Obeagu EI, Okoroiwu IL, Obeagu GU. Relationship between Thrombopoietin and Interleukin 3: A Review. Int J Curr Res Chem Pharm. Sci. 2022;9(1):7-13.
29. Ukonu UC, Nwosu DC, Okoroiwu LI, Dike-Ndudim JN, Ukonu GO, Obeagu EI. Evaluation of Alloantibodies to human platelet antigen and Leucocyte antigen class 1 in Multitransfused patients in Owerri, Imo state. Int. J. Curr. Res. Med. Sci. 2023;9(1):38-44.
30. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
31. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
32. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
33. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
34. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
35. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
36. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.

links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.

37. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
38. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
39. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
40. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
41. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
42. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
43. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
44. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
45. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.

46. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
47. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
48. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
49. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
50. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163.
51. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna University Journal of Medicine and Health Sciences. 2022;2(2):91-97.
52. Ezimah AC, Obeagu EI, Asur A, Ezimah UA, Ezimah CO. Absolute platelet count in adult patients with musculoskeletal pain: Current perspectives. Int. J. Curr. Res. Med. Sci. 2016;2(2):30-7.
53. Obeagu EI, Ogunnaya FU. Pregnancyinduced Haematological Changes: A Key to Maternal and Child Health. European Journal of Biomedical. 2023;10(8):42-43.
54. Obeagu EI, Chikelu IM, Obarezi TN, Ogbuabor BN, Anaebo QB. Haematological effects of fluted pumpkin (Telfairia occidentalis) leaves in rats. International Journal of Life Sciences Biotechnology and Pharma Research. 2014;3(1):172-182.
55. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
56. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
57. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University

journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69

58. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
59. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
60. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
61. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
62. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
63. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
64. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
65. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
66. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
67. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
68. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.

69. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
70. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
71. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
72. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
73. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
74. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
75. Alum EU, Ugwu OP, Aja PM, Obeagu EI, Inya JE, Onyeije AP, Agu E, Awuchi CG. Restorative effects of ethanolic leaf extract of Datura stramonium against methotrexate-induced hematological impairments. Cogent Food & Agriculture. 2023;9(1):2258774.
76. Igwe MC, Obeagu EI. Determination of the Effect of Methanol Extract of Tetrapleura Tetraptera Fruit Osmotic Fragility of Erythrocytes, Platelet Aggregation and Phospholipase A2 Activity. Ann. Clin. Lab. Res. 2018; 6:250-255.
77. Obeagu EF, Onyenweaku FC, Nwobodo HA, Ochei KC, Ochiabuto Ogochukwu MT, Onwuasoanya UF. Impact of HIV and hepatitis b virus coinfection on selected haematological markers of the patients in Umuahia, Abia State, Nigeria. Ann Clin Lab Res. 2017;5(2):175.
78. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-148.
79. Oke OT, Eyitayo EF, Obeagu EI. Inhalation effect of insecticides on some Haematological parameters of rabbits. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9):1-9.
80. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.

81. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
82. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
83. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
84. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
85. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
86. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
87. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
88. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
89. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
90. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
91. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
92. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
93. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.

94. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
95. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
96. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
97. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
98. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
99. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
100. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6.
101. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9):e37354.
102. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
103. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
104. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
105. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
106. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
107. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
108. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
109. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
110. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.

111. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
112. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
113. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
114. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
115. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
116. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
117. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
118. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
119. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
120. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
121. Hottz ED, Bozza FA, Bozza PT. Platelets in immune response to virus and immunopathology of viral infections. Frontiers in medicine. 2018; 5:121.
122. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
123. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
124. Perkins MV, Joseph SB, Dittmer DP, Mackman N. Cardiovascular disease and thrombosis in HIV infection. Arteriosclerosis, thrombosis, and vascular biology. 2023;43(2):1751-91.
125. Henning RJ, Greene JN. The epidemiology, mechanisms, diagnosis and treatment of cardiovascular disease in adult patients with HIV. American journal of cardiovascular disease. 2023;13(2):101.
126. Hsue PY. Mechanisms of cardiovascular disease in the setting of HIV infection. Canadian Journal of Cardiology. 2019;35(3):238-48.

127. Croda J, Croda MG, Neves A, dos Santos SD. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Critical care medicine. 2009;37(5):1605-1611.